Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24‐h intragastric pH and serum gastrin in healthy subjects

Warrington, Steve; Baisley, Kathy; Boyce, Malcolm; Tejura, Bina; Morocutti, Anna; Miller, Neil

doi:10.1046/j.1365-2036.2002.01292.x

Cited by 62 publications

(58 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…where rabeprazole was found to be a better antisecretory agent than esomeprazole. [20] In this study, improvement was seen in all five domains of QOLRAD scoring with both the drugs. But the improvement with rabeprazole was found to be more than esomeprazole over 1 month.…”

Section: Discussionmentioning

confidence: 53%

Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety

Maiti¹,

Jaida²,

Israel

et al. 2011

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

Objective:To compare the efficacy and safety of rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease (GERD).Materials and Methods:A randomized, single-blinded, outdoor-based clinical study was conducted on 60 patients of mild-to-moderate erosive GERD. After baseline clinical assessment and investigations, rabeprazole (40 mg) was prescribed to 30 patients and esomeprazole (40 mg) to another 30 patients for 4 weeks. The efficacy variables were change in GERD symptom scoring, endoscopic findings, and Quality of Life in Reflux and Dyspepsia (QOLRAD) scoring over 4 weeks.Result:Heartburn, acid regurgitation, and overall GERD symptom scoring (P = 0.01) were significantly decreased with rabeprazole in comparison to esomeprazole. The comparative study of all five domains of the QOLARD questionnaire including overall scoring revealed a statistically significant improvement in the rabeprazole group. Endoscopic findings in the rabeprazole group showed an absolute improvement of 30% and relative improvement of 55% over esomeprazole. Both the drugs were well tolerated having no significant difference in the incidence of adverse effects.Conclusion:Rabeprazole (40 mg) is a better choice for mild-to-moderate GERD compared with esomeprazole (40 mg) because of its better efficacy and safety profile.

show abstract

Section: Discussionmentioning

confidence: 53%

Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety

Maiti¹,

Jaida²,

Israel

et al. 2011

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

show abstract

“…4 Rabeprazole has a greater capacity to increase gastrin levels than other proton pump inhibitors. 5,6 This might explain why, in the present case, the patient's panic symptoms disappeared after rabeprazole was switched to esomeprazole. The mechanism whereby high serum concentrations of rabeprazole induce psychotic disorder is unknown, however.…”

Section: Discussionmentioning

confidence: 65%

Dissociative disorder induced by clarithromycin combined with rabeprazole in a patient with gastritis

Feng

Huang

et al. 2013

J Int Med Res

View full text Add to dashboard Cite

Clarithromycin and rabeprazole are both valued for their safety profile. Very few cases of adverse side-effects related to these drugs, when given individually, have been reported; serious side-effects of clarithromycin in combination with rabeprazole have never been reported. The present case reports on a 51-year-old woman with gastritis who received clarithromycin combined with rabeprazole for Helicobacter pylori infection. After taking 500 mg clarithromycin and 10 mg rabeprazole orally she displayed acute psychotic symptoms of dissociative disorder, including: impairment of orientation and attention; the feeling of dreaming; disintegration of thinking; stereotyped speech; flattened emotion; amnesia. Routine blood investigations, computed tomography scans and electroencephalography showed no abnormalities. All symptoms disappeared without antipsychotic treatment ≈ 48 h after she had taken the two drugs. Combining clarithromycin with rabeprazole might increase the risk of neurotoxicity, particularly in susceptible individuals. This should be a concern in clinical practice.

show abstract

“…The outcome of these rather rigorous inclusion criteria and design was a difficulty in fulfilling our initial goal of recruiting a large cohort of patients. Finally, from a number of candidate PPIs, we chose rabeprazole, since this drug has a number of potential advantages: (a) a rapid onset of action as shown by gastric pH monitoring studies [3,12,13] ; (b) a good safety profile; (c) a lack of drug interactions due to its specificity in terms of hepatic and non-hepatic metabolic pathways [4,5] ; and (d) its effectiveness in the treatment of some symptoms associated with GERD [14] . The results of our study are consistent with other studies of PPI tests which have without exception demonstrated the high sensitivity and poor specificity of this diagnostic approach [1] .…”

Section: Discussionmentioning

confidence: 99%

Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: Results of a study in a primary care setting

Varannes

Sacher‐Huvelin²,

Vavasseur³

et al. 2006

WJG

View full text Add to dashboard Cite

AIM: T o d e t e r m i n e t h e d i a g n o s t i c v a l u e o f t h e rabeprazole test in patients seen by general practitioners. METHODS:Eighty-three patients with symptoms s u g g e s t i v e o f G E R D w e r e e n r o l l e d b y g e n e r a l practitioners in this multi-centre, randomized and doubleblind study. All patients received either rabeprazole (20 mg bid) or a placebo for one week. The diagnosis of GERD was established on the presence of mucosal breaks at endoscopy and/or an abnormal esophageal 24-h pH test. The test was considered to be positive if patients reported at least a "clear improvement" of symptoms on a 7-point Likert scale. RESULTS:The sensitivities of the test for rabeprazole and the placebo were 83% and 40%, respectively. The corresponding specificity, positive and negative predictive values were 45% and 67%, 71% and 71%, and 62% and 35%, respectively. A receiver operating characteristics (ROC) analysis confirmed that the best discriminatory cut-off corresponded to description of "clear improvement". CONCLUSION:The poor specificity of the proton-pump inhibitor (PPI) test does not support such an approach to establish a diagnosis of GERD in a primary care setting.

show abstract

Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24‐h intragastric pH and serum gastrin in healthy subjects

Cited by 62 publications

References 16 publications

Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety

Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety

Dissociative disorder induced by clarithromycin combined with rabeprazole in a patient with gastritis

Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: Results of a study in a primary care setting

Contact Info

Product

Resources

About